A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical trial.
A new initiative, led by the Indian Medical Association (IMA) and the Federation of Obstetric and Gynaecological Societies of ...
An investigational therapeutic vaccine showed clinical effectiveness in patients with human papillomavirus (HPV)16-positive ...
Hosted on MSN21h
HPV vaccination: A game-changer in preventing cervical cancerWith 90 to 95 per cent of cervical cancer cases caused by the human papillomavirus (HPV), vaccination offers a nearly 99 per cent protection rate against the disease. Prince Court Medical Centre ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback